Navigation Links
ACD Wins $3 Million Grant From National Cancer Institute to Develop Its CTCscope™ System for Detection and Molecular Analysis of Circulating Tumor Cells

HAYWARD, Calif., Oct. 8 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) was awarded a three-year, $3 million grant from National Cancer Institute (NCI) under its SBIR Phase II Bridge Award. This grant will support ACD's continuing effort to develop its proprietary CTCscope™ system capable of automatic detection and molecular characterization of circulating tumor cells (CTCs). CTCs are the rare tumor cells detached from solid tumors and circulating in cancer patients' blood.

"We are very grateful for the continued support from NCI. The previous Phase I and Phase II grants have helped ACD to develop the underlying RNAscope™ technology, which has since been translated successfully into Research Use Only products for in situ detection of RNA biomarkers in FFPE samples," commented by Dr. Yuling Luo, President & CEO of ACD.  "Given how few of these grants are given, the award is a further validation of the strength of our technology to uniquely fulfill a critical unmet clinical need in cancer management." ACD has since been featured as one of the NCI SBIR Success Stories (

In this latest grant, ACD will work with a multidisciplinary team from four leading institutions to further advance CTCscope™ into an automated system and conduct clinical studies to demonstrate its clinical utility. Collaborators include Dr. Paul Goodwin of Applied Precision, Drs. Hope Rugo and John Park of University of California San Francisco, Prof. David Krag of University of Vermont, and Prof. Charles Coombes of Imperial College London.

About CTCscope™:

ACD's CTCscope™ system is based on its proprietary in situ RNA detection platform RNAscope™, which enables highly sensitive and specific detection of all types of CTCs without the need for EpCAM-based enrichment. Importantly, CTCscope™ is the only technology that detects those CTCs still alive while circulating in cancer patients' blood. These are the rare tumor cells that have the potential to metastasize to distant sites and thus are the targets of chemo- and targeted therapies. CTCscope™ identifies the molecular phenotypes of CTCs for guiding treatment decisions and allows real-time monitoring of therapy response.

About Advanced Cell Diagnostics (

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope™ technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management.Contact: Steve Chen, Ph.D. Chief Operating Officer (510) 576-8800 ext 102

SOURCE Advanced Cell Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. Atritech Announces Completion of a $22 Million Equity Financing
3. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
4. EntreMed Raises $20 Million to Support Clinical Development Program
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
7. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
8. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
Post Your Comments:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):